

A single night in hypoxia either with or without ketone ester ingestion reduces sleep quality without impacting next day exercise performance

1 Myrthe Stalmans¹, Domen Tominec², Robberechts Ruben¹, Wout Lauriks¹, Monique
2 Ramaekers¹, Tadej Debevec^{2,3}, Chiel Poffé^{1,4} #

3 ¹ Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven,
4 Leuven, Belgium

5 ² Faculty of Sport, University of Ljubljana, Ljubljana, Slovenia

³ Department of Automatics, Biocybernetics and Robotics, Jožef Stefan Institute, Ljubljana,
Slovenia

⁴ REVAL – Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt
University, Diepenbeek, Belgium

6 #, **Correspondence:** Chiel Poffé, REVAL – Rehabilitation Research Center, Faculty of
7 Rehabilitation Sciences, Hasselt University, Wetenschapspark 7, 3590 Diepenbeek, Belgium

8 Email: chiel.poffe@uhasselt.be

9 **Running head:** Ketones do not impact sleep in hypoxia

10 **Keywords:** ketone; sleep; recovery; oxygen saturation; exercise performance; hypoxia

11 ABSTRACT

12 **Background:** Sleeping at (simulated) altitude is highly common in athletes as an integral
13 part of altitude training camps or sport competitions. However, it is also often feared due to
14 proclaimed negative effects on sleep quality, thereby potentially hampering exercise recovery
15 and next-day exercise performance. We recently showed that ketone ester (KE) ingestion
16 beneficially impacted sleep following strenuous, late evening exercise in normoxia, and
17 alleviated hypoxemia. Therefore, we hypothesized that KE ingestion may be an effective
18 strategy to attenuate hypox(em)ia-induced sleep dysregulations. **Methods:** Eleven healthy,
19 male participants completed three experimental sessions including normoxic training and
20 subsequent sleep in normoxia or at a simulated altitude of 3,000m while receiving either KE
21 or placebo post-exercise and pre-sleep. Sleep was evaluated using polysomnography, while
22 next-day exercise performance was assessed through a 30-min all-out time trial (TT_{30'}).
23 Physiological measurements included oxygen status, heart rate variability, ventilatory
24 parameters, blood acid-base balance and capillary blood gases. **Results:** Hypoxia caused a
25 ~3% drop in sleep efficiency, established through a doubled wakefulness after sleep onset and
26 a ~22% reduction in slow wave sleep. KE ingestion alleviated the gradual drop in SpO₂
27 throughout the first part of the night, but did not alter hypoxia-induced sleep dysregulations.
28 Neither KE, nor nocturnal hypoxia affected TT_{30'} performance, but nocturnal hypoxia
29 hampered heart rate recovery following TT_{30'}. **Conclusion:** We observed that sleeping at
30 3,000m altitude already impairs sleep efficiency. Although this hypoxia-induced sleep
31 disruption was too subtle to limit exercise performance, we for the first time indicate that
32 sleeping at altitude impairs next-day exercise recovery. KE alleviated nocturnal hypoxemia
33 whenever SpO₂ values dropped below ~85%, but this did not translate into improved sleep or
34 next-day exercise performance.

35 **Word count:** 273

36 INTRODUCTION

37 Sleeping at (simulated) altitude is highly common in athletes as an integral part of
 38 altitude training camps. However, athletes are also often enforced to sleep at altitude during
 39 major sport competitions such as grand tours in cycling, Olympic Games, multi-day
 40 ultrarunning races or mountaineering expeditions. During altitude training camps, nocturnal
 41 hypoxic exposure is considered essential for inducing favorable physiological adaptations in
 42 the longer term such as increased hemoglobin mass and maximal oxygen consumption rates
 43 which may ultimately improve endurance exercise performance (1). Conversely, sleeping at
 44 altitude is also often feared by athletes – especially during competitions – due to proclaimed
 45 negative effects of hypoxia on sleep quality which may in turn hamper exercise recovery and
 46 next-day exercise performance.

47 In this respect, studies generally observed that a single night at (simulated) altitudes
 48 above 2,000 m impairs sleep quality (2–10). This is evidenced by decreases in either rapid eye
 49 movement (REM) or slow wave sleep (SWS), or an increase in wakefulness during the night.
 50 Methodological heterogeneity and contradictory findings, however, hinder unequivocal
 51 conclusions and a clear rationale. In general, REM sleep is unaffected at altitudes up to
 52 3,800m (2, 4, 6, 7, 11–13) but decreases up to 40% at altitudes starting from 4,000m (3, 5, 9,
 53 10). Data on SWS is much more equivocal with some studies reporting no changes at altitudes
 54 up to 3,800m (7, 11, 12), while other studies reported decreases from ~20-45% at altitudes
 55 between 2,000 and 4,300m (2, 5, 6, 9, 13). This is generally accompanied by an increased
 56 wakefulness after sleep onset (WASO) (3–7, 9). Conversely, sleep efficiency typically
 57 remains unaffected by altitudes of up to 4,000m (2–4, 6, 7, 11–13), but decreases by 10-20%
 58 at 4,000m (3, 13) and higher (9).

59 Sleep disturbances may have both direct and indirect implications for athletic performance.
60 This is evidenced by studies showing that a single night of restricted sleep (i.e., sleep time
61 reduction of 2-4h) increases cardiac stress during and after exercise on the next day (14).
62 Furthermore, ~5 days of disturbed sleep has been shown to suppress myofibrillar and
63 sarcoplasmic protein synthesis rates (15, 16), to impair insulin sensitivity (17), and to reduce
64 mitochondrial respiratory function (16). Although some studies reported no impact of sleep
65 restriction down to 2h per night on next day exercise performance (14, 18), other studies
66 indicated that a single night of ~2-3h sleep deprivation is sufficient to decrease 6s peak
67 cycling power output and both 3 and 20 km cycling time-trial performance (19, 20).
68 Nevertheless, it is currently unknown if the more subtle differences in sleep quality and
69 quantity that are expected to occur upon a single night in hypoxia also impair next day
70 exercise performance.

71 The precise underlying mechanisms of hypoxia-induced sleep impairments are currently
72 unknown. Yet, they are most likely caused by hypoxemia (8, 12, 21, 22). Interestingly, we
73 previously showed that increasing blood ketone bodies (KB), via oral ketone ester (KE)
74 ingestion, attenuated the drop in blood (as well as muscle and brain) oxygenation after 3-4h in
75 hypoxia (23, 24). Furthermore, we identified that KE intake post-exercise and pre-sleep
76 beneficially impacted sleep following strenuous, late evening exercise in normoxic
77 conditions. This was evidenced by an inhibition of late evening exercise-induced decreases in
78 REM sleep and WASO, and a 2% improvement in sleep efficiency (25).

79 These data indicate that pre-sleep KE ingestion may be an effective strategy to attenuate
80 hypox(em)ia-induced sleep dysregulations. Against this background, this study aims to
81 identify the impact of a single night in hypoxia on (i) nocturnal sleep measured using golden
82 standard polysomnography, and (ii) next day exercise performance, and to (iii) explore the

- 83 potential of KE supplementation to counteract potential performance or sleep dysregulations
- 84 under these conditions.

85 METHODS

86 *Ethical approval and participants.* This research was registered at www.clinicaltrials.gov
87 (NCT06060093) and approved by the Ethics Committee Research UZ/KU Leuven
88 (B3222022001041). Potential participants were medically screened and provided written
89 informed consents. Candidates' sleep quality was screened using the Pittsburgh Sleep Quality
90 Index (PSQI) in order to guarantee adequate baseline sleep quality as defined by the National
91 Sleep Foundation (i.e., sleep efficiency above 85%). Participants working in late-night shifts,
92 as well as extreme morning and evening chronotypes as determined by the Horne-Östberg
93 questionnaire were excluded. All thirteen healthy, male participants that were included
94 reported good sleep quality and no indications for sleep disorders (PSQI score <5). None of
95 them showed indications for psychological or neurological disorders, such as depression
96 (Beck's Depression questionnaire) or anxiety (Beck's Anxiety questionnaire). All participants
97 were active in cycling, endurance running or triathlon. Further exclusion criteria included
98 smoking, exposure to altitudes >1,500m during the 3 months preceding the study or a history
99 of altitude-sensitive pathologies. From the thirteen participants that were initially included,
100 one dropped out due to a Covid-19 infection and another one was excluded from the data
101 analyses due to a baseline sleep quality drastically below the predefined inclusion criteria
102 (i.e., sleep efficiency of 78%). Therefore, data analyses were performed on 11 participants
103 [age: 24 ± 4 yr; height: 181.3 ± 7.5 m; body mass: 73.2 ± 9.2 kg; physical activity: 8 ± 3
104 h.week⁻¹, $\dot{V}\text{O}_2\text{max}$: 61.5 ± 8.8 mL.kg⁻¹.min⁻¹ (mean $\pm$ SD)].

105 *General study design.* This randomized, double-blind, placebo-controlled, cross-over
106 study consisted of three experimental sessions. These sessions were designed to mimic a live-
107 high, train-low setup, and all included an identical training session in normoxia whereafter
108 participants either spend the night in (i) normoxia (N_{PL}) or (ii) normobaric hypoxia (~3,000m
109 simulated altitude) while receiving a placebo (H_{PL}), or in (iii) hypoxia while receiving KE

(H_{KE} , Fig. 1). Following the night in either hypoxia or normoxia, participants performed an all-out 30min time-trial ($TT_{30'}$) to evaluate exercise performance. Physiological measurements were performed at rest throughout both days of the protocol. This design allowed us to evaluate both (i) the impact of sleeping in hypoxia vs. normoxia, and (ii) the potential of KE to improve sleep in hypoxia. All experimental sessions were conducted in a normobaric hypoxic facility (Van Amerongen CA Technology, Tiel, The Netherlands) at the Bakala Athletic Performance Center (Leuven, Belgium). The experimental sessions were separated by a one-week wash-out period, and experimental protocols and timings were identical for all three sessions.

Preliminary testing and familiarization sessions. Two weeks before the first experimental session, participants performed a familiarization session consisting of a graded exercise test on a cycling ergometer (Avantronic Cyclus II, Leipzig, Germany) to assess both their lactate threshold (LT) and maximal oxygen uptake rate ($\dot{V}\dot{O}_{2max}$). For the LT determination, initial workload was set at 70W and increased by 40W per 8min. Capillary blood samples were obtained every 4min for determination of blood lactate concentration (Lactate Pro2; Arkray, Amstelveen, The Netherlands), with LT being defined as the lowest workload provoking a 1 mM blood [lactate] increase within the same stage (25–27). After 15min of active recovery at 70W, participants started a second incremental cycling test (100W + 25W/30sec) until volitional exhaustion. Throughout this test, oxygen consumption ($\dot{V}\dot{O}_2$) and carbon dioxide production ($\dot{V}\dot{CO}_2$) rates were measured continuously using indirect calorimetry (Cortex Metalyzer 3B, Cortex, Leipzig, Germany), and $\dot{V}\dot{O}_{2max}$ was calculated as the highest $\dot{V}\dot{O}_2$ over a 30-sec period.

In the 2 weeks before the first experimental session, participants performed the full experimental protocol twice in normoxia to get accustomed to the experimental procedures, exercise protocols, and sleeping facility. Starting from the first familiarization session,

participants were asked to maintain a stable sleep schedule until the final experimental session. This included the requirement to sleep 7-9h per night, with bed-time between 10-12 PM and wake-time between 6-8 AM. Compliance to a stable sleep-wake schedule was assessed throughout the entire study period via a sleep diary and actigraphy (Actigraph wGT3X-BT, ActiGraph LLC, Pensacola, Florida, US). Moreover, sleep quality of the night prior to each experimental session was also assessed using the St. Mary's Sleep questionnaire.

Experimental sessions. After waking up at their individually predetermined time, participants arrived in a fasted state between 7.00 and 9.00 AM at the testing facility (exact timings were replicated for each session). 2.5h after consuming a standardized breakfast (see *Dietary standardization* below), they performed a 2-h morning endurance training session (ET_{120'}) on a cycling ergometer (Tacx Neo Smart, Wassenaar, The Netherlands). ET_{120'} consisted of eight consecutive 15-min intervals with workload alternating between 60% and 80% of LT. 1.5h after lunch time, participants completed an 80-min high intensity interval training (HIIT_{80'}) on a cycling ergometer (Avantronic Cyclus II, Leipzig, Germany). HIIT_{80'} consisted of a 10-min warm up at 70% of LT, followed by 10 repetitions of 3min at 120% of LT interspersed by 4min active recovery at 50% of LT. Thirty minutes after HIIT_{80'} (~5h before sleep-time), participants entered their individual 'hotel room' that was set at either hypoxia (H_{PL} and H_{KE}; F_IO₂: 14.5% O₂, P_IO₂: ~110 mmHg, ~3,000m simulated altitude) or normoxia (N_{PL}; F_IO₂: 20.9% O₂, P_IO₂: ~160 mmHg). Subsequently participants resided for 16h under these environmental conditions, with sleep being measured in each condition using polysomnography (PSG). Following 16h of hypoxia/normoxia, participants returned to normoxia and exercise performance was assessed 3.5h later by means of an all-out 30-min time trial (TT_{30'}). In addition, physiological measurements were performed at rest at the following timepoints: (i) before ET_{120'} (baseline, 0h), (ii) after 2h in hypoxia or equivalent in normoxia (+10h), (iii) immediately upon waking up (+23h), and (iv) 2h after returning to

normoxia (+27h). These measurements included determination of heart rate (HR), heart rate variability (HRV), ventilatory parameters, and blood, brain and skeletal muscle oxygenation.

Supplementation protocol. In a randomized order, participants received 25g of either a ketone ester [H_{KE}, 96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, KetoneAid Inc., Falls Church, Virginia, USA] or a placebo (N_{PL} and H_{PL}, details below) supplement immediately after (i) ET_{120'} and (ii) HIIT_{80'}, (iii) after 1.5h in hypoxia (or equivalent in normoxia), and (iv) 30min before sleep. Hence, in H_{KE} participants received a total dose of 100g ketone ester (1.39 ± 0.17 g·kg⁻¹ body weight) in order to intermittently elevate blood ketone bodies post-exercise and throughout the first part of the night. In N_{PL} and H_{PL}, participants received a total of 100g of a taste and viscosity matched, inert placebo consisting of 12.5% w/v collagen (6d Sports Nutrition, Oudenaarde, Belgium) and 1 mM bitter sucrose octaacetate (Sigma-Aldrich, Bornem, Belgium) dissolved in water. In total, caloric intake via the KE supplements was ~700 kcal vs. ~0 kcal for the placebo supplements. Randomization was performed by a researcher who was otherwise not involved in the study.

Dietary standardization. The evening before each experimental session, participants consumed a standardized carbohydrate-rich dinner at home (~5,600 kJ; 69% carbohydrate, 16% fat, 15% protein). Water consumption was allowed *ad libitum* until arrival at the facility the next morning, and was replicated for each session. After participants arrived at the testing facility in a fasted state, they consumed a standardized breakfast (~4,200 kJ; 68% carbohydrate, 21% fat, and 11% protein). Subsequently participants received a carbohydrate-rich snack (~660 kJ; 92% carbohydrate, 3% fat, and 5% protein) 1h before ET_{120'}, and received 60g carbohydrates per hour during ET_{120'} via isotonic drinks and carbohydrate-rich snacks (6d Sports Nutrition, Oudenaarde, Belgium). A light lunch (~4,150 kJ; 74% carbohydrate, 25% fat, and 14% protein) was provided 1.5h before HIIT_{80'}, and participants

received a high-carbohydrate, high-protein recovery shake (60g carbohydrate, 30g protein, 6d Sports Nutrition, Oudenaarde, Belgium) immediately after HIIT_{80'}. After 30min in hypoxia/normoxia, a standardized dinner (~3,250 kJ; 69% carbohydrate, 5% fat, and 26% protein) was served while participants received a light snack (~1,700 kJ of which 69 % carbohydrates, 15 % protein, 16 % fat) 2h before sleep time in order to prevent participants from going to bed hungry. Hence, total caloric intake on the first day – excluding the KE supplements – was ~3,590 kJ. The next morning, participants received an identical breakfast as on the first day, and received a carbohydrate-rich snack (cfr. before ET_{120'}) 30min before TT_{30'}.

Nocturnal measurements.

Polysomnography (PSG). A digital amplifier (V-amp, Brain Products, Gilching, Germany) was used to record sleep quality and quantity during the experimental sessions, and data were digitized at a sampling rate of 1000 Hz. According to the international 10 – 20 system, electroencephalographic (EEG) recordings were made from Fz, Cz, Pz, Oz, C3, C4, A1, and A2 where the A2 electrode served as the reference electrode and A1 as a backup reference. A ground electrode was positioned in the middle of the forehead. Eye movements (vertical/horizontal) were recorded with electrooculographic (EOG) electrodes above and under the right eye and with electrodes attached to the outer cantus of both eyes. A 0.1 Hz low cut-off filter and a 30 Hz high cut-off filter were applied to both EEG and EOG data. Submental muscle tone and movements were assessed with an electromyogram (EMG) of the chin, recorded with a low cut-off filter of 10 Hz and a high cut-off filter of 200 Hz. Electrical noise was filtered out with a 50 Hz notch filter. A blinded, independent, certified sleep technician (Sleep Well PSG, Canada) visually scored night recordings following the Rechtschaffen & Kales guidelines, in conjunction with the AASM guidelines, in 30 s epochs.

A 0.3 – 35 Hz, 0.3 – 30 Hz, and a 10 – 100 Hz bandpass filter was used for EEG, EOG and EMG signals, respectively. The assessed sleep variables were: (i) total sleep time, (ii) WASO, (iii) total NREM and REM sleep, (iv) total N1, N2, and REM and SWS sleep, (v) sleep onset, sleep onset to N2, SWS, and REM sleep, (vi) sleep efficiency (total sleep time/time in bed), and (vii) amount of awakenings.

Sleep event detection. EEG data were preprocessed in BrainVision Analyzer (Brain Products GmbH, Gilching, Germany). After applying a 0.1 – 30 Hz bandpass filter, data were transferred to a Python environment (version 3.10.5). Detection of both ‘slow waves’ and ‘sleep spindles’ was performed according to previously described guidelines (28). For each channel, the densities of slow waves and sleep spindles were averaged across the channels for N2 and SWS phases.

Oxygen saturation and HR. During the participants’ registered sleep time, blood oxygen saturation (SpO₂) and HR were continuously assessed using pulse oximetry (Nellcor PM10N, Medtronic, Minneapolis, USA). These data were used to calculate both average and minimal HR, the minimal SpO₂, the average nocturnal SpO₂ both over the entire night, as well as within 10% epochs of the night. Furthermore, variation in SpO₂ was assessed through a coefficient of variation (CV) for every hour ($CV_i = SD_i / \text{mean}_i$ with i = the hour of the night) in agreement with an earlier study (29). CV_i was calculated given earlier evidence that periodic breathing causes fluctuations in nocturnal oxygen saturation in preterm infants (30).

Resting measurements. All resting measurements were performed by the same trained researcher. Measurements were performed throughout a 10min time-window and with the participants being in supine position for at least 10min before the start of the first measurement. Data for all parameters are presented as the average values of the last minute.

Blood and tissue oxygenation status. Blood oxygen saturation (SpO₂) was assessed using a pulse oximeter (Nellcor PM10N, Medtronic, Minneapolis, USA) with an infrared sensor placed ~2 cm above the left eyebrow and with sampling frequency set at 2 Hz. Cerebral and skeletal muscle oxygenation status were assessed by means of tissue oxygenation index (cTOI and mTOI, resp.) using near infrared spectroscopy (NIRS). The probes of a NIRO-200 spectrometer (Hamamatsu, Japan) were attached ~2 cm above the right eyebrow (cerebral oxygenation) and centrally on the belly of the right *m. vastus lateralis* (skeletal muscle oxygenation). A constant penetration depth of ~2 cm into the muscle/brain tissue was ensured by inserting the emitter and detector probes in a dark-colored rubber spacer, maintaining a fixed interoptode distance of 4 cm. These spacers were attached to the participants using an elastic non-transparent bandage and double-sided adhesive tape to prevent displacement or interference from external light. Before each experimental session, the participants' skin was shaved and cleaned to exclude any signal disturbance by hair or impurities. Moreover, exact inter-session replication was guaranteed by marking the contour lines of the rubber spacer on the skin. Participants were asked to preserve and refresh these marks during the washout period in order to maintain this position during the following sessions. After experimental data collection, NIRS data were preprocessed (Matlab R2023a, The Mathworks, Natick, MA) over 1-min long time chunks using a fourth-order Butterworth filter with a cut-off frequency of 0.05 Hz (24).

Heart rate and heart rate variability. Resting HR and RR-peak intervals were measured using a Polar H10 (Polar, Kempele, Finland). HRV was analyzed by using the percentage of adjacent NN intervals that differ by more than 50 ms (pNN50), the root mean square of successive differences (RMSSD), and absolute power of the high-frequency band (HF) using Kubios (Kubios HRV Standard 3.5.0, Kubios Oy, Kuopio, Finland).

Ventilatory gas exchange measurements. Indirect calorimetry (Cortex Metalyzer 3b, Leipzig, Germany) was used to measure breath-by-breath gas exchange data [*i.e.*, minute ventilation ($\dot{V}_E$), oxygen uptake rate ($\dot{V}O_2$) and carbon dioxide production rate ($\dot{V}CO_2$)].

Exercise performance. After returning to normoxia on the second day, participants performed $TT_{30'}$ which was preceded by a 15-min warm-up at 70% of LT on a cycling ergometer (Avantronic Cyclus II, Leipzig, Germany). Participants were instructed to achieve an average power output as high as possible and were allowed to voluntarily change the applied workload every 5min in the initial 25min, and every 1min during the final 5min. The starting workload was determined during the familiarization sessions, where initial power in the first session was set at the LT and in the second as the average power output of the first $TT_{30'}$. In turn, the average of the second $TT_{30'}$ functioned as the starting workload of both experimental $TT_{30'}$.

Capillary blood, urine sampling and analyses.

Capillary samples. Before breakfast (baseline, 0h), thirty min after every supplement ingestion (+5.5h, +9h and +11h and +13h), and immediately upon waking up on the second morning (+23h), a capillary blood sample was obtained for immediate determination of D- β -hydroxybutyrate (GlucoMen Areo 2K-meter with β -ketone sensor strips, A. Menarini Diagnostics, Firenze, Italy). In addition, 70 μ l capillary blood was collected from a hyperemic earlobe into a capillary tube (safeCLINITUBE, Radiometer Medical ApS, Copenhagen, Denmark) before every resting measurement (baseline, +10h, +23h and +27h) and immediately before sleep (+13h). After immediate mixing for 10sec, samples were analyzed

for acid-base balance, p50, and pCO₂ (ABL90 FLEX analyzer, Radiometer Medical ApS, Copenhagen, Denmark).

Urine samples. Immediately before sleep time, participants emptied their bladder and nocturnal urine was collected until wake-up in urine flasks prepared with 10 mL hydrochloric acid. A small volume (~10 mL) of urine was frozen (-80 °C) for subsequent analyses of adrenaline, noradrenaline, and dopamine using a commercially available ELISA kit (BA E-6600, LDN, Nordhorn, Germany) within 4 weeks after the final experimental session.

Statistical analyses. All statistical analyses were performed in GraphPad Prism version 10.1.2 (GraphPad Software, La Jolla, CA, USA). Prior to statistical testing, normal distribution of the data was evaluated and confirmed with the D'Agostino-Pearson normality test for SpO₂ and HR during the night as well as power output and HR during TT_{15'}. One way analysis of variance (ANOVA) was used to evaluate differences between conditions for measurements obtained at a single time point during each session. Data collected at multiple time points within a given experimental session were analyzed by means of a two-way repeated measures ANOVA. A Geisser-Greenhouse correction was applied whenever the assumption of sphericity was violated (Mauchly's test, JASP version 0.18.1, JASP Team, Amsterdam, The Netherlands). In case of a significant main or interaction effect, *post-hoc* analyses were performed using Šidák's correction. When applicable, reported p-values refer to these post-hoc analyses and otherwise, p-values for main effects were included. All data are presented as mean ± SD and statistical significance was defined as p < 0.05. An a-priori sample size calculation was performed based on the effect size of KE on sleep efficiency (i.e., primary outcome of the current study) that was derived from our previous study investigating the effect of KE during sleep in normoxia (25). Power analysis (G*Power version 3.1.9.7) indicated that a sample size of 6 per condition is required to establish a significant effect on

307 sleep efficiency (effect size η_p^2 : 0.45; α error: 0.05; power: 0.80; correlation among repeated
308 measures: 0.5; nonsphericity correction: 1; ANOVA: repeated measures, within factors).

RESULTS

Blood β HB concentrations. A time x condition effect was observed for blood [β HB] ($p < 0.001$, Fig. 2). Baseline concentrations were low (~ 0.4 mM) in all conditions, and concentrations remained low (~ 0.4 - 0.5 mM) throughout the entire protocol in N_{PL} and H_{PL} . Conversely, blood [β HB] consistently increased to 2-3 mM (range: 1.4 to 4.7 mM) thirty min after ingestion of each KE supplement. Upon waking up the second day of the protocol, blood [β HB] had returned to baseline values in all conditions.

Sleep architecture. Time in bed was kept constant for a given subject across all conditions and was on average 512 ± 25 min. Compared to N_{PL} , H_{PL} decreased sleep efficiency by 3% ($p = 0.037$, Fig. 3a). This was mediated by a doubling ($+ \sim 17$ min) of WASO ($p = 0.049$, Fig. 3b), increased number of arousals ($p = 0.027$, Fig. 3c) while sleep onset latency ($p = 0.316$, Fig. 3d), and latencies of N2, SWS and REM phases remained unaffected (all $p > 0.29$, data not shown). The reduced sleep efficiency in H_{PL} vs. N_{PL} was accompanied by a $\sim 22\%$ reduction in SWS ($p = 0.002$, Fig. 3e), and a $\sim 39\%$ increase in N1 duration ($p = 0.034$, Fig. 3f), while N2 phase and REM sleep duration remained unaffected ($p > 0.271$, Fig. 3g-h, resp.). KE did not affect any of the hypoxia-induced dysregulations as all parameters were similar between H_{PL} and H_{KE} (all $p > 0.340$). Densities of both sleep spindles and slow waves during N2 ($p = 0.082$ and $p = 0.307$, resp.) and SWS ($p = 0.752$ and $p = 0.782$, resp.) were unaffected throughout the experimental sessions (data not shown).

Subjective sleep quality. A main effect was observed for the following questions in the St. Mary's sleep questionnaire; 'How deep was your sleep?' (N_{PL} : 5 ± 1 , H_{PL} : 4 ± 1 , H_{KE} : 4 ± 1 ; $p = 0.007$), 'How many times did you wake up?' (N_{PL} : 3 ± 1 , H_{PL} : 4 ± 2 , H_{KE} : 4 ± 1 ; $p = 0.007$), 'How clear-headed did you feel after getting up this morning?' (N_{PL} : 4 ± 1 , H_{PL} : $2 \pm$

1, H_{KE} : 3 ± 1 ; $p = < 0.001$), ‘How satisfied were you with last night’s sleep?’ (N_{PL} : 4 ± 1 , H_{PL} : 3 ± 1 , H_{KE} : 3 ± 1 ; $p = 0.015$). Post-hoc analyses indicated that, compared to N_{PL} , participants in H_{PL} perceived that they slept less deep, woke up more times during the night, felt less clear-headed after getting up and were less satisfied with their night’s sleep. Except for a more clear-headed feeling upon waking up in H_{KE} ($p = 0.012$ vs. H_{PL}), no differences were observed between H_{PL} and H_{KE} . No effects were observed for the questions ‘How much sleep did you have last night?’ (N_{PL} : 8 ± 1 , H_{PL} : 7 ± 1 , H_{KE} : 8 ± 1 ; $p = 0.099$), ‘How much sleep did you have during the day, yesterday?’ (N_{PL} : 0 ± 0 , H_{PL} : 0 ± 0 , H_{KE} : 0 ± 0), ‘How well did you sleep last night?’ (N_{PL} : 4 ± 1 , H_{PL} : 3 ± 1 , H_{KE} : 3 ± 1 ; $p = 0.051$), ‘Were you troubled by waking early and being unable to get off to sleep again?’ (N_{PL} : 1 ± 1 , H_{PL} : 0 ± 1 , H_{KE} : 1 ± 0 ; $p = 0.123$) and ‘How much difficulty did you have in getting off to sleep last night?’ (N_{PL} : 1 ± 1 , H_{PL} : 2 ± 1 , H_{KE} : 1 ± 0 ; $p = 0.224$)

Nocturnal oxygen saturation and heart rate. At the start of the night, SpO_2 was 9% lower in H_{PL} compared to N_{PL} ($p < 0.001$, Fig. 4a). Throughout the first half of the night, SpO_2 gradually decreased in all conditions, reaching minimal SpO_2 levels after ~220min in bed or ~44% of sleep for all conditions ($p = 0.954$ and $p = 0.921$, resp., data not shown). Due to both lower baseline values and a steeper reduction throughout the night in H_{PL} vs. N_{PL} , minimal and average SpO_2 were respectively 20 and 13% lower in H_{PL} compared to N_{PL} ($p < 0.001$, Fig. 4b-c). KE ingestion alleviated the gradual drop in SpO_2 throughout the first part of the night (Fig. 4a). Hence, SpO_2 after 40% of the night, as well as minimal SpO_2 were both 4% higher in H_{KE} vs. H_{PL} ($p = 0.029$ and $p = 0.048$, Fig. 4a and Fig. 4b, resp.). Conversely, average nocturnal SpO_2 was similar between H_{KE} and H_{PL} ($p = 0.519$ vs. H_{PL} , Fig. 4c).

H_{PL} strongly increased the CV of SpO_2 during all hours of the night compared to N_{PL} ($p < 0.002$, Fig. 4d). This increase in CV was attenuated by KE ingestion during the 2nd hour of

the night ($p = 0.008$ vs. H_{PL}), but not at any of the other timepoints. Compared to N_{PL} , H_{PL} increased minimal and average nocturnal HR by respectively $\sim 10\%$ and $\sim 20\%$ ($p = 0.008$ and $p < 0.001$ vs. N_{PL} , resp, Fig. 4e-f). KE further increased minimal nocturnal HR by $\sim 8\%$ ($p = 0.019$ for H_{KE} vs. H_{PL}), and tended to further elevate average nocturnal HR ($p = 0.079$ for H_{KE} vs. H_{PL}).

Exercise performance. Mean power output during $TT_{30'}$ was similar between all conditions at ~ 285 W [$p = 0.454$, confidence interval (CI): -5 to +9 W for N_{PL} vs. H_{PL} and -9 to +12 for H_{KE} vs. H_{PL} , Fig. 5a,b). Also average HR during $TT_{30'}$ (Fig. 5c) was similar between all conditions ($p = 0.251$). However, after 5 min of passive recovery, participants HR remained ~ 6 -9 bpm higher in H_{PL} and H_{KE} compared to N_{PL} ($p < 0.001$, Fig. 5d)

Resting measurements – oxygen status, heart rate and heart rate variability. A time x condition effect was detected for SpO_2 ($p < 0.001$, Table 1). Compared to N_{PL} , SpO_2 dropped to a similar extent in H_{PL} and H_{KE} both at +10h ($p < 0.001$ vs. N_{PL}) and +23h ($p < 0.001$ vs. N_{PL}). Conversely, both cTOI and mTOI remained stable at respectively $\sim 73\%$ and $\sim 67\%$ in all experimental conditions (data not shown). For HR, a time x condition effect was found ($p < 0.001$, Table 1). Post-hoc analyses indicated that HR was $\sim 14\%$ higher in H_{PL} vs. N_{PL} at +10h ($p < 0.001$), and even $\sim 20\%$ higher at +23h ($p < 0.001$). KE ingestion further increased resting HR at +10h ($p < 0.001$ vs. H_{PL}). An interaction effect was observed for all measured HRV indices (pNN50, $p = 0.002$; RMSSD, $p < 0.001$; HF, $p = 0.005$; Table 1). Compared to N_{PL} , H_{PL} lowered pNN50, RMSSD and HF at +10h, while at +23h only pNN50 and RMSSD were decreased. KE did not alter the impact on RMSSD, but lowered pNN50 and HF at +23h compared to H_{PL} .

Resting measurements – acid-base balance, blood gasses and ventilatory parameters.

Blood pH, p50, pCO₂, as well as ventilatory parameters were similar between all conditions at baseline (Table 2). Compared to N_{PL}, H_{PL} increased blood pH at +10h and +23h but not at +27h, while pCO₂ was decreased at all timepoints. Conversely, p50 remained similar between N_{PL} and H_{PL} at all timepoints. Relative to H_{PL}, H_{KE} caused a slight acidosis at +10h which was accompanied by a KE-induced reduction in pCO₂, and an increase in p50. Each of these KE-induced alterations were again normalized at +23h and +27h. Irrespective of the experimental condition, V̇E was similar at baseline (11.5 ± 0.2 L.min⁻¹), increased at +10h (13.1 ± 0.2 L.min⁻¹, p < 0.001 vs. baseline) and decreased at +23h (9.9 ± 0.4 L.min⁻¹, p = 0.001 vs. baseline). V̇O₂ was similar at baseline (0.161 ± 0.014 L.min⁻¹) and increased at +10h (0.236 ± 0.009 L.min⁻¹, p = 0.004 vs. baseline). Also V̇CO₂ was similar at baseline (0.182 ± 0.012 L.min⁻¹) yet decreased at +27h (0.0125 ± 0.017 L.min⁻¹, p = 0.018 vs. baseline).

Nocturnal catecholamine excretion.

Nocturnal urine production was similar in all conditions (N_{PL}: 679 ± 375 mL, H_{PL}: 626 ± 223 mL, H_{KE}: 685 ± 321 mL, p = 0.647). Also nocturnal adrenaline (N_{PL}: 5.86 ± 3.66 nmol, H_{PL}: 6.93 ± 4.16 nmol, H_{KE}: 6.60 ± 4.14 nmol, p = 0.305), noradrenaline (N_{PL}: 52.5 ± 22.2 nmol, H_{PL}: 50.3 ± 10.8 nmol, H_{KE}: 56.7 ± 12.4 nmol, p = 0.608) and dopamine (N_{PL}: 911 ± 305 nmol, H_{PL}: 795 ± 229 nmol, H_{KE}: 956 ± 350 nmol, p = 0.324) excretions were unaffected by the different conditions.

DISCUSSION

Sleeping at (simulated) altitude is increasingly common in athletes either as part of altitude training camps or due to competitions at such altitudes. Earlier studies indicated that, starting from ~2,000m, this typically causes an acute reduction in sleep quality (2–10) thereby potentially impairing exercise recovery and readiness to perform. We recently observed that KE ingestion counteracts sleep disruptions induced by late-evening exercise under normoxic conditions (25). Furthermore, KE has also been shown to attenuate hypoxemia, which is considered the primary mechanism underlying hypoxia-induced sleep disturbances (23, 24). Therefore, we investigated whether KE ingestion could counteract sleep disruptions induced by sleeping at altitude (i.e., 3,000m), and impact next day endurance exercise performance. Sleeping at altitude impaired sleep quality as evidenced by a 3% reduction in sleep efficiency, a doubling of WASO and a ~20% reduction in slow wave sleep. These sleep disturbances did not affect performance during a 30-min time-trial the next day, but reduced subsequent heart rate recovery. KE slightly alleviated nocturnal hypoxemia but was unable to negate these sleep disruptions, nor impacted next day exercise performance or subsequent heart rate recovery.

Based on the available literature, sleeping at 3,000m altitude is expected to increase WASO (3–7, 9) and potentially decrease slow wave sleep (2, 5, 6, 9, 13), while REM sleep and sleep efficiency generally remain unaffected up to altitudes of ~4,000m (2, 4, 6, 7, 11–13). Although our results on WASO, slow wave sleep and REM are in line with available literature, we observed that even lower simulated altitudes (i.e. 3,000 m) can already elicit a drop in sleep efficiency. As sleep efficiency depicts the time spent asleep over the time spent in bed, with the latter standardized over all sessions, this drop was established by a decreased time asleep through a doubling in WASO. The divergent vs. convergent effects on respectively SE and WASO between our study and earlier studies likely resulted from the fact

that we, in contrast to most of the earlier studies, standardized the total time in bed. This is supported by two earlier studies showing that under free-living conditions the observed increase in nocturnal wakefulness upon altitude is at least in part compensated by a ~5% increase in time in bed (6, 7). Nevertheless, this increase in time in bed failed to reach statistical significance in both studies.

Increased awakenings upon hypoxia are generally attributed to a hypoxia-induced periodic breathing pattern (5, 31). This phenomenon almost exclusively occurs during NREM sleep and especially during SWS, and causes short awakenings or arousals and disruption of SWS. Our observations indicating that hypoxia decreases SWS but not REM sleep, together with an increased amount of arousals, thus indirectly endorse the important role of periodic breathing in hypoxic sleep impairment. This is further supported by our observation that hypoxia drastically increased the periodic variation of SpO₂ during the night, which is a central hallmark of periodic breathing (29).

Sleep disturbances can evoke a myriad of negative effects on processes implicated in exercise performance, training adaptation, and general health. This is evidenced by studies showing that large reductions in sleep quantity (reductions of 2-3 h.night⁻¹ for 1 to 5days) for instance increase heart rate during submaximal exercise (14), suppress myofibrillar and sarcoplasmic protein synthesis rates (15, 16), and impair mitochondrial respiratory function (16) and insulin sensitivity (17). Although some studies reported a concomitant drop in both sprint and endurance cycling performance (19, 20), even such large sleep disruptions do not always evoke impairments in exercise performance (14, 18). However, to our knowledge, no data is available on the impact of more subtle sleep disturbances such as those observed in our study.

The minor sleep disturbances induced by hypoxia in our study did not affect $TT_{30'}$ performance, nor altered resting heart rate, heart rate variability or respiratory parameters the day after. However, the (disrupted) night in hypoxia compromised heart rate recovery after $TT_{30'}$ as evidenced by the ~10 bpm higher heart rate in H_{PL} vs. N_{PL} five min after completion of $TT_{30'}$. A reduced or delayed heart rate recovery reflects an impaired vagal activity (32), a strong predictor for morbidity (33), which is generally associated with cardiovascular disease (34) and overtraining (35). This impaired heart rate recovery upon hypoxia may be related to the hypoxia-induced reduction in SWS. Indeed, selective SWS suppression was previously found to disrupt sympathovagal balance by decreasing vagal tone (36) and stimulation of slow waves during sleep improved next day cardiac function, as evidenced through an improved left-ventricular systolic function (37, 38). This indicates that although exercise performance was not affected after one disrupted night, more subtle changes are present which may in the longer term impact exercise recovery, performance or general (cardiovascular) health.

In contrast to our hypothesis, KE ingestion did not counteract the hypoxia-induced sleep dysregulations. This conflicts with our earlier data showing that KE intake negated the sleep disruptions induced by strenuous late evening exercise under normoxic conditions (25). A potential explanation for these contrasting observations are the disparate effects of strenuous late evening exercise vs. hypoxia on sleep architecture. Both conditions caused a decrease in sleep efficiency and an increase in WASO. However, while strenuous late evening exercise decreased REM sleep without affecting NREM sleep, hypoxia did not affect REM sleep but decreased SWS. This suggests that ketosis may only beneficially impact sleep when REM is disrupted. This is supported by an earlier study showing that a ketogenic diet improved REM sleep in children with epilepsy (39), a condition typically associated with reduced REM sleep (40). More recent data collected by our group during a 7-week exercise training program confirms this hypothesis as KE only increased REM sleep relative to a placebo group

whenever REM sleep dropped below baseline values (Robberechts et al., unpublished observations). We previously suggested that the ability of KE to counteract reductions in REM sleep was mediated through an increased dopamine signaling following KE ingestion (41, 42), as dopamine plays an important role in the transition from NREM to REM sleep (43). However, in contrast to our earlier studies, KE intake did not affect nocturnal dopamine excretion in the current study.

An important factor in compromised hypoxic sleep is hypoxemia, and subsequent periodic breathing. As described above, periodic breathing induces periods of hypopnea and apnea causing short awakenings especially during SWS (12). As minimal SpO₂ values are closely related to the apneic part of a periodic breathing cycle (44), the observed KE-induced increase (~+3%) in minimal SpO₂ and SpO₂ at 40% of sleep duration together with the diminished variance in nocturnal SpO₂ after 2h of sleep suggest a slightly tempered periodic breathing behavior after KE ingestion. However, this effect was likely too small to translate in sleep improvements. As nocturnal respiration was not recorded in the current study, further research is required to identify if KE may impact periodic breathing.

On the other hand, hypoxemia activates a wide array of adaptive responses, amongst others establishing the respiratory alkalosis observed in H_{PL}, causing a left-shift of the oxyhemoglobin dissociation curve (ODC) and thus favoring a higher SpO₂ for a given pO₂. Ingestion of KE, contrarily, established a relative metabolic acidosis in agreement with earlier data (23, 24), thereby pushing a right-shift of the ODC as evidenced by the observed increase in p50. Nevertheless, average nocturnal SpO₂ values were similar after ingestion of KE compared to PL and only after 40% of sleep duration, SpO₂ was higher in KE. This can at least partly be explained by the higher capillary pO₂ values that were observed immediately before sleep, i.e. after 5h in hypoxia, in H_{KE} (56.8 ± 3.4 mmHg) vs. H_{PL} (53.3 ± 4.0 mmHg) thereby compensating the right shift of the ODC. It should however be highlighted that pO₂

values were obtained using a capillary sampling method, which might underestimate actual arterial pO_2 .

As indicated above, KE increased SpO_2 at 40% of the night, as well as minimal nocturnal SpO_2 , but did not impact SpO_2 at any other timepoint. This is most likely related either to (i) the extent of hypoxemia or (ii) to the specific duration of ketosis or hypoxic exposure. This is supported by our two earlier studies showing that KE attenuated hypoxemia only after ~3-4h of hypoxic exposure and ketosis, and whenever SpO_2 values were below ~82% (23, 24). These requirements were fulfilled at 40% of the night, but not at the other timepoints where we measured SpO_2 . For instance, at +10h participants were in ketosis but had only resided in hypoxia for 2h, while at +23h, participants had resided in hypoxia for 14h however were no longer in ketosis. Furthermore, at the start of the night SpO_2 values were around 90% while during the final part of the night participants were most likely no longer in ketosis (25).

Besides hypoxemia, ketone bodies may also affect sleep by altering sympathetic nervous activity. In line with literature (45, 46), hypoxia caused an increase in both resting and nocturnal heart rate, as well as a decrease in all HRV parameters on the first evening of the protocol thereby suggesting a relative dominance of the sympathetic nervous system. Upon waking up however, HF values had recovered but RMSSD and pNN50 values remained depressed. While RMSSD and pNN50 are measures for overall HRV, HF isolates the high-frequency component (0.12-0.4 Hz) of the spectrum and entails information on ventilation and respiratory sinus arrhythmias (RSA), a phenomenon explaining fluctuation of HR and HRV together with natural breathing (47–49). As natural breathing is disrupted in hypoxia, both through periodic breathing and consistent hyperventilation, HF was indeed expected to increase (49). While SWS is associated with low heart rate variability in normoxia (50), sympathetic nerve activity is even higher during REM sleep compared to being awake (51). Although the exact relationship between sleep and sympathetic activity remains unclear, it

cannot be ruled out that this increased sympathetic dominance is linked to the hypoxia-induced disruption of SWS. However, whether this is either a cause or a consequence remains to be identified.

Despite unaffected nocturnal adrenaline and noradrenaline concentrations, KE lowered HRV indices pNN50 and RMSSD upon waking up and increased nocturnal HR. This indicates that, in line with earlier studies performed both in normoxia (25, 52, 53) and hypoxia (23), KE ingestion further promoted sympathetic dominance. In this context, through manipulation of sympathetic activity, ketone bodies may only potentially benefit sleep quality when REM sleep, and not SWS, is disrupted.

In conclusion, we observed that a single night of hypoxic exposure (~3,000m altitude) has a detrimental impact on sleep quality, through reduced sleep efficiency, SWS, and increased WASO. While this did not impact next day exercise performance, it hampered post-exercise heart rate recovery suggesting that sleeping at (simulated) altitude has minor implications for athlete training management. Contrary to our expectations, ketone ingestion did not mitigate any of these effects. However, we confirmed earlier data showing that KE can alleviate hypoxemia whenever SpO₂ values drop below ~82% and whenever subjects are at least for 3-4h in ketosis. Taken together with our earlier observations, ingestion of ketones as a strategy to improve sleep and recovery appears effective when REM sleep is disrupted (e.g., through late-evening exercise) whereas disruption of NREM sleep (through hypoxic exposure) remains unaffected.

ADDITIONAL INFORMATION

Competing interests

The authors declare that they have no competing interests.

Author contributions

All experiments were performed within the Exercise Physiology Research Group and the Bakala Academy-Athletic Performance Center at the KU Leuven, Belgium. Conception and design of the study: MS, TD and CP. Data collection and/or data analyses: MS, DT, WL, RR, MR, TD and CP. Interpretation of the data and manuscript drafting: MS and CP. All authors critically revised the manuscript and approved the final version of the manuscript.

Funding

This research was supported by the Research Foundation – Flanders (FWO Weave, research grant G073522N) and Slovene Research Agency grant (N5-0247). CP is supported by an FWO senior postdoctoral research grant (12B0E24N).

Acknowledgements

The authors wish to thank all participants for their dedicated cooperation in this study. We also thank Ms. Monique Ramaekers for skillful assistance during the experimental trials.

TABLES

Table 1. Effect of hypoxia (H_{PL} vs. N_{PL}) and ketone ester (KE) ingestion (H_{KE} vs. H_{PL}) on blood oxygen saturation (SpO_2), heart rate (HR) and heart rate variability (HRV).

	N_{PL}	H_{PL}	H_{KE}
SpO_2 (%)			
Baseline	97.4 ± 1.7	98.5 ± 1.5	98.7 ± 1.3
+10h	98.2 ± 1.1	$87 \pm 4 \text{ \#}$	$88.5 \pm 4.5 \text{ \#}$
+23h	98.1 ± 2.1	$89.2 \pm 2.6 \text{ \#}$	$90.8 \pm 3.3 \text{ \#}$
+27h	98.2 ± 1.7	97.9 ± 1.7	98.7 ± 1
HR (bpm)			
Baseline	60.1 ± 6.1	60.7 ± 5.1	57.6 ± 6.1
+10h	$65.6 \pm 7.8 \text{ \#}$	$74.9 \pm 8.6 \text{ \#}$	$84.8 \pm 7 \text{ \#*}$
+23h	$51.4 \pm 6.3 \text{ \#}$	$61.3 \pm 9.7 \text{ \#}$	$63.6 \pm 8.4 \text{ \#}$
+27h	$55.2 \pm 6.4 \text{ \#}$	56.9 ± 6.9	58.2 ± 7.8
pNN50 (%)			
Baseline	43.4 ± 21.6	45.2 ± 24.8	52.5 ± 23.2
+10h	34.4 ± 23.5	$14.1 \pm 19.2 \text{ \#}$	$4.2 \pm 7.6 \text{ \#}$
+23h	59.5 ± 24.9	$38.3 \pm 21.3 \text{ \#}$	$22.3 \pm 17.1 \text{ \#*}$
+27h	47.4 ± 23.5	50.1 ± 27.0	51.9 ± 23.2
RMSSD (ms)			
Baseline	75.4 ± 41.7	74.2 ± 29.3	86.7 ± 37.4
+10h	62.7 ± 43.1	$32.1 \pm 22.2 \text{ \#}$	$21.3 \pm 20.6 \text{ \#}$
+23h	94.2 ± 38.4	$70.3 \pm 36.2 \text{ \#}$	$50.8 \pm 28.2 \text{ \#}$
+27h	88.9 ± 38.1	96.8 ± 51.6	87.8 ± 38.5
HF (log)			
Baseline	7.42 ± 1.00	7.46 ± 0.72	$7.41 \pm 1.00 \text{ \#}$
+10h	7.04 ± 1.00	$5.67 \pm 1.19 \text{ \#}$	$4.75 \pm 1.56 \text{ \#}$
+23h	7.07 ± 0.99	7.14 ± 0.91	$6.46 \pm 1.16 \text{ *}$
+27h	7.48 ± 1.34	7.5 ± 1.25	7.62 ± 1.05

During a randomized, cross-over protocol, participants received either ketone ester (KE) or placebo (PL) supplements and spent the night either at a simulated altitude of 3,000m (H_{PL} and H_{KE}) or in normoxia (N_{PL}). Participants' blood oxygen saturation (SpO_2), heart rate (HR) and heart rate variability (HRV) were assessed at baseline, after 2h in hypoxia/normoxia (+10h), immediately upon waking up in hypoxia/normoxia (+23h) and 2h after returning to normoxia (+27h). Mean values $\pm$ SD (n=11) are shown for SpO_2 , HR, the percentage of adjacent NN intervals that differ by more than 50 ms (pNN50), the root mean square of successive differences (RMSSD), and the absolute power of the high-frequency band (HF). $\text{\#}$, $p < 0.05$ vs. N_{PL} ; *, $p < 0.05$ vs. H_{PL} ; #, $p < 0.05$ vs. baseline.

Table 2. Effect of hypoxia (H_{PL} vs. N_{PL}) and ketone ester (KE) ingestion (H_{KE} vs. H_{PL}) on blood acid base balance and capillary blood gases.

	N_{PL}	H_{PL}	H_{KE}
pH			
Baseline	7.409 ± 0.016	7.412 ± 0.013	7.406 ± 0.011
+10h	7.419 ± 0.021	7.438 ± 0.017 §#	7.395 ± 0.016 §#*
+13h	7.414 ± 0.014	7.433 ± 0.018 §#	7.412 ± 0.027
+23h	7.421 ± 0.013 #	7.451 ± 0.026 §#	7.457 ± 0.009 §#
+27h	7.417 ± 0.015	7.431 ± 0.016 #	7.432 ± 0.018 #
p50 (mmHg)			
Baseline	26.2 ± 0.5	25.9 ± 0.7	25.9 ± 0.9
+10h	25.1 ± 1 #	25.9 ± 0.7	26.8 ± 1.3 §*
+13h	25.8 ± 0.9	25.8 ± 1	25.5 ± 1.4
+23h	25.3 ± 1.3	25 ± 1	24.4 ± 1 §#
+27h	25.6 ± 1.1	25.7 ± 0.6	25.1 ± 1.2
pCO₂ (mmHg)			
Baseline	41.2 ± 2.2	42 ± 1.8	41.8 ± 1.7
+10h	42.4 ± 1.1	40.9 ± 1.4 §	38 ± 1.2 §*
+13h	42.4 ± 1.6	40 ± 2 §	37.3 ± 2 §*
+23h	41.5 ± 2.2	37 ± 2.1 §	36.7 ± 1.5 §
+27h	42.3 ± 1.7	39.4 ± 1.6 §	39 ± 1.9 §

During a randomized, cross-over protocol, participants received either ketone ester (KE) or placebo (PL) supplements and spent the night either at a simulated altitude of 3,000m (H_{PL} and H_{KE}) or in normoxia (N_{PL}). Participants' capillary blood was analyzed baseline, after 2h in hypoxia/normoxia (+10h), immediately before sleep (+13h) and upon waking up in hypoxia/normoxia (+23h) and 2h after returning to normoxia (+27h). Capillary blood pH, p50 and pCO₂ were evaluated. §, $p < 0.05$ vs. N_{PL} ; *, $p < 0.05$ vs. H_{PL} ; #, $p < 0.05$ vs. baseline.

FIGURES

Figure 1. Schematic representation of the experimental protocol that was designed to mimic a live-high train-low (LHTL) strategy. In a double-blind, randomized, crossover design, 11 participants completed three experimental sessions each involving a two-day protocol. On day 1, subjects performed two exercise training sessions [120 min endurance training (ET_{120'}) and 80 min high intensity interval training (HIIT_{80'})] in normoxia followed by a night either in normoxia (N), or at a simulated altitude of 3,000m (H). After each training session and before sleep, participants received either placebo (N_{PL} and H_{PL}) or ketone ester (H_{KE}) supplements. On day 2, exercise performance was evaluated by means of a 30-min all-out time trial (TT_{30'}). Sleep quality and architecture were assessed via polysomnography. Physiological measurements were performed in a resting state at baseline, after 2h in hypoxia or equivalent in normoxia, immediately upon waking up and 2h after return to normoxia in order to assess blood oxygen saturation, cerebral and muscular oxygenation status, ventilatory gas exchange, heart rate and heart rate variability. In addition, before every resting measurement, as well as immediately before sleep time, a capillary blood sample was collected for determination of acid-base balance, and blood gasses.




Figure 2. Blood D-β-hydroxybutyrate concentrations ([βHB]) are presented in response to ingestion of ketone ester (KE) or placebo (PL) supplements during experimental sessions including a night (dark grey zone) either in normoxia (N_{PL}, black, open circles) or at a simulated altitude of 3,000m (grey dotted zone; H_{PL}, black and H_{KE}, red full circles). Blood [βHB] was assessed at baseline, 30min after the morning endurance training (ET_{120'}; +5.5h) and the afternoon high intensity interval training (HIIT_{80'}; +9h), as well as after 2h in hypoxia/normoxia (+11h), immediately before sleep (+13h) and upon waking up (+23h). Mean (line) ± SD (whiskers), as well as individual values are shown for n = 11. §, p < 0.05 vs. N_{PL}; #, p < 0.05 vs. baseline for indicated condition.




Figure 3. Data of polysomnographic (PSG) recordings are shown for participants that completed three experimental sessions in which they received either ketone ester (KE) or placebo (PL) supplements. They spent the night either in normoxia (N_{PL}) or at a simulated altitude of 3,000m (H_{PL} and H_{KE}). During the night, participants' sleep was recorded using polysomnography (PSG). Mean (bar plots) $\pm$ SD (whiskers), as well as individual values are shown for a) sleep efficiency, b) wakefulness after sleep onset (WASO), c) the amount (#) of arousals per night, and d) sleep onset latency (SOL). Moreover, sleep stage durations are shown for e) slow wave sleep (SWS), f) N1 phase, g) N2 phase, and h) rapid eye movement (REM) sleep. Data are reported for 11 participants and datapoints are connected within each participant. §, $p < 0.05$ vs. N_{PL} .




Figure 4. Nocturnal measurements of blood oxygen saturation (SpO_2) and heart rate (HR) are shown for participants that completed three experimental sessions in which they received either ketone ester (KE) or placebo (PL) supplements. They spent the night either in normoxia (N_{PL}) or at a simulated altitude of 3,000m (H_{PL} and H_{KE}). Mean (circles) $\pm$ SD (whiskers) are shown for a) SpO_2 throughout the percentual duration of the night (%). Mean (bar plots) $\pm$ SD (whiskers), as well as individual values are shown for b) average and c) minimal nocturnal SpO_2 and d) coefficient of variance of SpO_2 per hour of the night, as well as e) average and f) minimal nocturnal HR. Data are reported for 11 participants and individual values are connected within each participant. §, $p < 0.05$ vs. N_{PL} ; #, $p < 0.05$ vs. baseline; ##, $p < 0.05$ vs. baseline for H_{PL} and H_{KE} ; *, $p < 0.05$ for H_{KE} vs. H_{PL} .





Figure 5. Exercise performance and heart rate data are shown for participants that completed three experimental sessions in which they received either ketone ester (KE) or placebo (PL) supplements during the first day. After spending the night in either in normoxia (N_{PL}) or at a simulated altitude of 3,000m (H_{PL} and H_{KE}), exercise performance was assessed by an all-out 30-min time trial ($TT_{30'}$). Mean (bar plots) $\pm$ SD (a, c, d, whiskers) or mean (horizontal indication) $\pm$ 95% confidence intervals (b, whiskers), as well as individual values are shown for a) mean power output, b) the individual differences in mean power output between all experimental conditions and c) average heart rate (HR) during $TT_{30'}$ and d) HR after 5min of passive recovery. Data are reported for 11 participants and individual values are connected within each participant §, $p < 0.05$ vs. N_{PL} .



REFERENCES

1. **Levine BD, Stray-Gundersen J.** “Living high-training low”: Effect of moderate-altitude acclimatization with low-altitude training on performance. *J Appl Physiol* 83: 102–112, 1997. doi: 10.1152/jappl.1997.83.1.102.
2. **Hoshikawa M, Uchida S, Sugo T, Kumai Y, Hanai Y, Kawahara T.** Changes in sleep quality of athletes under normobaric hypoxia equivalent to 2,000-m altitude: A polysomnographic study. *J Appl Physiol* 103: 2005–2011, 2007. doi: 10.1152/japplphysiol.00315.2007.
3. **Mizuno K, Asano K, Okudaira N.** Sleep and Respiration under Acute Hypobaric Hypoxia. *Jpn. J. Physiol.* 43: 161–175, 1993.
4. **Pedlar C, Whyte G, Emegbo S, Stanley N, Hindmarch I, Godfrey R.** Acute sleep responses in a normobaric hypoxic tent. *Med Sci Sports Exerc* 37: 1075–1079, 2005. doi: 10.1249/01.mss.0000171623.52757.0f.
5. **Reite M, Jackson D, Cahoon RL, Weil J V.** Sleep physiology at high altitude. *Electroencephalogr Clin Neurophysiol* 38: 463–471, 1975.
6. **Selvamurthy W, Raju VRK, Ranganathan S, Hegde KS, Ray US.** Sleep patterns at an altitude of 3500 metres. *Int J Biometeorol* 30: 123–135, 1986. doi: 10.1007/BF02189452.
7. **Zieliński J, Koziej M, Mańkowski M, Sarybaev AS, Tursalieva JS, Sabirov IS, Karamuratov AS, Mirrakhimov MM.** The quality of sleep and periodic breathing in healthy subjects at an altitude of 3200 m. *High Alt Med Biol* 1: 331–336, 2000. doi: 10.1089/15270290050502408.
8. **Berssenbrugge BYA, Dempsey J, Iber C, Skatrud J, Wilson P.** Mechanisms of

- 658 Hypoxia-Induced Periodic Breathing During Sleep In Humans. *J Physiol* 343: 507–
659 524, 1983.
- 660 9. **De Aquino Lemos V, Antunes HKM, Dos Santos RVT, Lira FS, Tufik S, De Mello**
661 **MT.** High altitude exposure impairs sleep patterns, mood, and cognitive functions.
662 *Psychophysiology* 49: 1298–1306, 2012. doi: 10.1111/j.1469-8986.2012.01411.x.
- 663 10. **Finnegan TP, Abraham P, Docherty TB.** Ambulatory monitoring of the
664 electroencephalogram in high altitude mountaineers. *Electroencephalogr Clin*
665 *Neurophysiol* 60: 220–224, 1985. doi: 10.1016/0013-4694(85)90034-3.
- 666 11. **Kinsman TA, Gore CJ, Hahn AG, Hopkins WC, Hawley JA, McKenna MJ, Clark**
667 **SA, Aughey RJ, Townsend NE, Chow CM.** Sleep in athletes undertaking protocols of
668 exposure to nocturnal simulated altitude at 2650 m. *J Sci Med Sport* 8: 222–232, 2005.
669 doi: 10.1016/S1440-2440(05)80013-1.
- 670 12. **Normand H, Barragan M, Benoit O, Bailliant O, Raynaud J.** Periodic breathing and
671 O₂ saturation in relation to sleep stages at high altitude. *Aviat Sp Environ Med* 61:
672 229–235, 1990.
- 673 13. **Latshang TD, Lo Cascio CM, Stöwhas A-C, Grimm M, Stadelmann K, Tesler N,**
674 **Achermann P, Huber R, Kohler M, Bloch KE.** Are Nocturnal Breathing, Sleep, and
675 Cognitive Performance Impaired at Moderate Altitude (1630-2590 m)? *Sleep* 36:
676 1969–1976, 2013.
- 677 14. **Mougin F, Simon-Rigaud ML, Davenne D, Renaud A, Garnier A, Kantelip JP,**
678 **Magnin P.** Effects of sleep disturbances on subsequent physical performance. *Eur J*
679 *Appl Physiol Occup Physiol* 63: 77–82, 1991. doi: 10.1007/BF00235173.
- 680 15. **Saner NJ, Lee MJC, Pitchford NW, Kuang J, Roach GD, Garnham A, Stokes T,**

- 681 **Phillips SM, Bishop DJ, Bartlett JD.** The effect of sleep restriction, with or without
682 high-intensity interval exercise, on myofibrillar protein synthesis in healthy young
683 men. *J Physiol* 598: 1523–1536, 2020. doi: 10.1113/JP278828.
- 684 16. **Saner NJ, Lee MJC, Kuang J, Pitchford NW, Roach GD, Garnham A, Genders**
685 **AJ, Stokes T, Schroder EA, Huo Z, Esser KA, Phillips SM, Bishop DJ, Bartlett**
686 **JD.** Exercise mitigates sleep-loss-induced changes in glucose tolerance, mitochondrial
687 function, sarcoplasmic protein synthesis, and diurnal rhythms. *Mol Metab* 43: 101110,
688 2021. doi: 10.1016/j.molmet.2020.101110.
- 689 17. **Sweeney EL, Peart DJ, Kyza I, Harkes T, Ellis JG, Walshe IH.** Impaired insulin
690 profiles following a single night of sleep restriction: The impact of acute sprint interval
691 exercise. *Int J Sport Nutr Exerc Metab* 30: 139–144, 2020. doi:
692 10.1123/IJSNEM.2019-0235.
- 693 18. **Reilly T, Edwards B.** Altered sleep-wake cycles and physical performance in athletes.
694 *Physiol Behav* 90: 274–284, 2007. doi: 10.1016/j.physbeh.2006.09.017.
- 695 19. **Chase JD, Roberson PA, Saunders MJ, Hargens TA, Womack CJ, Luden ND.**
696 One night of sleep restriction following heavy exercise impairs 3-km cycling time-trial
697 performance in the morning. *Appl Physiol Nutr Metab* 42: 909–915, 2017. doi:
698 10.1139/apnm-2016-0698.
- 699 20. **Dean B, Hartmann T, Wingfield G, Larsen P, Skein M.** Sleep restriction between
700 consecutive days of exercise impairs sprint and endurance cycling performance. *J Sleep*
701 *Res* 32: 1–9, 2023. doi: 10.1111/jsr.13857.
- 702 21. **Nussbaumer-Ochsner Y, Ursprung J, Siebenmann C, Maggiorini M, Bloch KE.**
703 Effect of short-term acclimatization to high altitude on sleep and nocturnal breathing.

- 704 *Sleep* 35: 419–423, 2012. doi: 10.5665/sleep.1708.
- 705 22. **Weil J V.** Sleep at high altitude. *High Alt Med Biol* 5: 180–189, 2004. doi:
706 10.1089/1527029041352162.
- 707 23. **Stalmans M, Tominec D, Lauriks W, Robberechts R, Poffé C.** Exogenous ketosis
708 attenuates acute mountain sickness and mitigates high-altitude hypoxemia [Online].
709 <https://doi.org/10.1101/2023.11.21.23298762>.
- 710 24. **Poffé C, Robberechts R, Podlogar T, Kusters M, Debevec T, Hespel P.** Exogenous
711 ketosis increases blood and muscle oxygenation but not performance during exercise in
712 hypoxia. *Am J Physiol Integr Comp Physiol* 321: R844–R857, 2021. doi:
713 10.1152/ajpregu.00198.2021.
- 714 25. **Robberechts R, Albouy G, Hespel P, Poffé C.** Exogenous Ketosis Improves Sleep
715 Efficiency and Counteracts the Decline in REM Sleep after Strenuous Exercise. *Med*
716 *Sci Sports Exerc* 55: 2064–2074, 2023. doi: 10.1249/MSS.0000000000003231.
- 717 26. **Poffé C, Ramaekers M, Bogaerts S, Hespel P.** Bicarbonate Unlocks the Ergogenic
718 Action of Ketone Monoester Intake in Endurance Exercise. *Med Sci Sports Exerc* 53:
719 431–441, 2020. doi: 10.1249/MSS.0000000000002467.
- 720 27. **Poffé C, Wyns F, Ramaekers M, Hespel P.** Exogenous Ketosis Impairs 30-min Time-
721 Trial Performance Independent of Bicarbonate Supplementation. *Med Sci Sports Exerc*
722 53: 1068–1078, 2020. doi: 10.1249/MSS.0000000000002552.
- 723 28. **Nicolas J, King BR, Levesque D, Lazzouni L, Coffey E, Swinnen S, Doyon J,**
724 **Carrier J, Albouy G.** Sigma oscillations protect or reinstate motor memory depending
725 on their temporal coordination with slow waves. *Elife* 11: 1–26, 2022. doi:
726 10.7554/eLife.73930.

29. **von Czettritz G, Bax RT, Eckardt T, Springer S, Emmrich P.** [Periodic breathing with periodic oxygen variation in infancy]. *Wien Med Wochenschr* 146: 317–319, 1996.
30. **Razi NM, DeLauter M, Pandit PB.** Periodic breathing and oxygen saturation in preterm infants at discharge. *J Perinatol* 22: 442–444, 2002. doi: 10.1038/sj.jp.7210762.
31. **Salvaggio A, Insalaco G, Marrone O, Romano S, Braghiroli A, Lanfranchi P, Patruno V, Donner CF, Bonsignore G.** Effects of high-altitude periodic breathing on sleep and arterial oxyhaemoglobin saturation. *Eur Respir J* 12: 408–413, 1998. doi: 10.1183/09031936.98.12020408.
32. **Imai K, Sato H, Hori M, Kusuoka H, Ozaki H, Yokoyama H, Takeda H, Inoue M, Kamada T.** Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. *J Am Coll Cardiol* 24: 1529–1535, 1994. doi: 10.1016/0735-1097(94)90150-3.
33. **Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS.** Heart Rate Recovery Immediately After Exercise as a Predictor of Mortality. *J Cardiopulm Rehabil* 20: 131–132, 2000. doi: 10.1097/00008483-200003000-00012.
34. **Peçanha T, Silva-Júnior ND, Forjaz CL de M.** Heart rate recovery: Autonomic determinants, methods of assessment and association with mortality and cardiovascular diseases. *Clin Physiol Funct Imaging* 34: 327–339, 2014. doi: 10.1111/cpf.12102.
35. **Lamberts RP, Swart J, Capostagno B, Noakes TD, Lambert MI.** Heart rate recovery as a guide to monitor fatigue and predict changes in performance parameters. *Scand J Med Sci Sport* 20: 449–457, 2010. doi: 10.1111/j.1600-0838.2009.00977.x.

- 750 36. **Tasali E, Leproult R, Ehrmann DA, Van Cauter E.** Slow-wave sleep and the risk of
751 type 2 diabetes in humans. *Proc Natl Acad Sci U S A* 105: 1044–1049, 2008. doi:
752 10.1073/pnas.0706446105.
- 753 37. **Huwiler S, Carro-Domínguez M, Stich F, Sala R, Aziri F, Trippel A, Ryf T,**
754 **Markendorf S, Niederseer D, Böhm P, Stoll G, Laubscher L, Thevan J, Spengler**
755 **CM, Gawinecka J, Osto E, Huber R, Wenderoth N, Schmied C, Lustenberger C.**
756 Slow waves during deep sleep support cardiac function. *Curr Issues Sport Sci* 9: 4,
757 2024. doi: 10.36950/2024.2ciss004.
- 758 38. **Alessandrelli G, Huwiler S, Bernardi G, Carro-domínguez M, Stich F.**
759 Cardiovascular responses to natural and auditory evoked slow waves predict post-sleep
760 cardiac function. .
- 761 39. **Hallböök T, Lundgren J, Rosén I.** Ketogenic diet improves sleep quality in children
762 with therapy-resistant epilepsy. *Epilepsia* 48: 59–65, 2007. doi: 10.1111/j.1528-
763 1167.2006.00834.x.
- 764 40. **Sadak U, Honrath P, Ermis U, Heckelmann J, Meyer T, Weber Y, Wolking S.**
765 Reduced REM sleep: a potential biomarker for epilepsy – a retrospective case-control
766 study. *Seizure* 98: 27–33, 2022. doi: 10.1016/j.seizure.2022.03.022.
- 767 41. **Church WH, Adams RE, Wyss LS.** Ketogenic diet alters dopaminergic activity in the
768 mouse cortex. *Neurosci Lett* 571: 1–4, 2014. doi: 10.1016/j.neulet.2014.04.016.
- 769 42. **Robberechts R, Poffé C.** Defining ketone supplementation: the evolving evidence for
770 post-exercise ketone supplementation to improve recovery and adaptation to exercise.
771 *Am J Physiol Physiol* , 2023. doi: 10.1152/ajpcell.00485.2023.
- 772 43. **Hasegawa E, Miyasaka A, Sakurai K, Cherasse Y, Li Y, Sakurai T.** Rapid eye

- 773 movement sleep is initiated by basolateral amygdala dopamine signaling in mice.
774 *Science* (80-) 375: 994–1000, 2022. doi: 10.1126/science.abl6618.
- 775 44. **West JB, Peters RM, Aksnes G, Maret KH, Milledge JS, Schoene RB.** Nocturnal
776 periodic breathing at altitudes of 6,300 and 8,050 m. *J Appl Physiol* 61: 280–287, 1986.
777 doi: 10.1152/jappl.1986.61.1.280.
- 778 45. **Bernardi L, Passino C, Spadacini G, Calciati A, Robergs R, Greene R, Martignoni**
779 **E, Anand I, Appenzeller O.** Cardiovascular autonomic modulation and activity of
780 carotid baroreceptors at altitude. *Clin Sci* 95: 565–573, 1998. doi: 10.1042/cs0950565.
- 781 46. **Guyenet PG.** Neural structures that mediate sympathoexcitation during hypoxia.
782 *Respir Physiol* 121: 147–162, 2000. doi: 10.1016/S0034-5687(00)00125-0.
- 783 47. **Novak V, Novak P, De Champlain, J, Le Blanc R, Martin R, Nadeau R.** Influence
784 of Respiration on Heart Rate and Blood Pressure Fluctuations. *J Physiol* 74: 617–626,
785 1993. doi: 10.1201/b15277-5.
- 786 48. **Brown TE, Beightol LA, Koh J, Eckberg DL.** Important influence of respiration on
787 human R-R interval power spectra is largely ignored. *J Appl Physiol* 75: 2310–2317,
788 1993. doi: 10.1152/jappl.1993.75.5.2310.
- 789 49. **Morales JF, Deviaene M, Milagro J, Testelmans D, Buyse B, Willems R, Orini M,**
790 **Van Huffel S, Bailon R, Varon C.** Evaluation of Methods to Characterize the Change
791 of the Respiratory Sinus Arrhythmia with Age in Sleep Apnea Patients. .
- 792 50. **Brandenberger G, Ehrhart J, Piquard F, Simon C.** Inverse coupling between
793 ultradian oscillations in delta wave activity and heart rate variability during sleep. *Clin*
794 *Neurophysiol* 112: 992–996, 2001. doi: 10.1016/S1388-2457(01)00507-7.

- 795 51. **Somers VK, Dyken ME, Mark AL, Abboud FM.** Sympathetic-Nerve Activity
796 During Sleep in Normal Subjects. *N Engl J Med* 328: 303–307, 1993.
- 797 52. **Kolanowski J, Young JB, Landsberg L.** Stimulatory influence of d(–)3-
798 hydroxybutyrate feeding on sympathetic nervous system activity in the rat. *Metabolism*
799 43: 180–185, 1994.
- 800 53. **Robberechts R, Poffé C, Hespel P.** Exogenous ketosis suppresses diuresis and atrial
801 natriuretic peptide during exercise. *J Appl Physiol* : 449–460, 2022. doi:
802 10.1152/japplphysiol.00061.2022.
- 803
- 804